Pharma ADMET Testing Market Report 2026

Pharma ADMET Testing Market Overview

• Pharma ADMET Testing market size has reached to $10.7 billion in 2025 • Expected to grow to $19.27 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: The Impact Of Escalating Clinical Trials On The Pharma ADMET Testing Market • Market Trend: Artificial Intelligence Driven Drug Design And ADMET Prediction Redefining Pharma ADMET Testing With In Silico Platforms • Asia-Pacific was the largest region in 2025.

The key promising market opportunities in the pharma admet testing market include: • In Vitro ADMET Testing (Segmentation By Testing Type) → Expected gain of $4333.16 Million • High Throughput (Segmentation By Technology) → Expected gain of $3141.19 Million • Cell Culture (Segmentation By Technology) → Expected gain of $2687.33 Million

What Is Covered Under Pharma ADMET Testing Market?

Pharma ADMET testing refers to a set of procedures and assays used in the pharmaceutical industry to assess the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) of drug candidates. It is used for determining the safety and efficacy of potential drugs before they can be approved for clinical use. The main types of pharma ADMET testing are in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. In vivo ADMET testing refers to the assessment of a drug's absorption, distribution, metabolism, excretion, and toxicity properties within a living organism. Pharma ADMET testing is used in drug discovery and development processes to identify potential drug candidates with desirable pharmacokinetic properties. The technologies include cell culture, high throughput, molecular imaging, and OMICS technology which are used in systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others.

What Is The Pharma ADMET Testing Market Growth Forecast?

The pharma admet testing market size is expected to see rapid growth in the next few years. It will grow to $19.27 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing demand for cost-efficient drug development, rising adoption of predictive admet analytics, expansion of personalized medicine pipelines, growing integration of machine learning in drug testing, increasing outsourcing of admet testing services. Major trends in the forecast period include increasing adoption of in silico admet modeling tools, growing use of high-throughput screening technologies, expansion of AI-based toxicity prediction platforms, rising integration of omics data in drug testing, enhanced focus on early-stage drug safety evaluation.

What Is The Driver Of The Pharma ADMET Testing Market?

The increase in the number of clinical trials is expected to boost the growth of the pharma ADMET testing market going forward. A clinical trial is a research study conducted with human participants to evaluate the safety, efficacy, and potential side effects of a medical intervention, such as a new drug, medical device, diagnostic procedure, or treatment regimen. The upswing in clinical trials markedly elevates the demand for thorough assessments of drug safety and efficacy within the pharma ADMET testing market, emphasizing the critical need for tailored evaluations across diverse drug candidates and patient populations. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based nonprofit organization, the number of industry-initiated clinical trials in the UK grew from 411 trials in 2022 to 426 trials in 2023, marking a 3.7% increase. Therefore, the increase in the number of clinical trials is driving the growth of the pharma ADMET testing industry.

How Will The Drivers Impact Growth In The Global Pharma ADMET Testing Market?

• Expansion of High-Throughput Screening (HTS) Platforms (Medium) – During the forecast period, the expansion of high-throughput screening (hts) platforms will become a key driver of growth in the pharma admet market by 2030. as drug developers increasingly adopt hts technologies to rapidly evaluate large libraries of compounds for absorption, distribution, metabolism, excretion and toxicity (admet) properties, the demand for scalable and efficient admet testing services will rise. these platforms enable simultaneous early-stage screening of hundreds to thousands of compounds, reducing time-to-data, lowering costs per candidate, and enabling faster prioritization of safe and efficacious drug leads. as pharmaceutical and biotech companies accelerate discovery cycles and broaden their pipelines, especially with growing interest in small molecules and biologics, the need for robust, automated admet testing supported by hts infrastructure will expand rapidly, thereby driving growth of the pharma admet testing market. as a result, the expansion of high-throughput screening (hts) platforms is anticipated to contributing to a 1.5% annual growth in the market. • Shift Toward Complex Biologics and Novel Modalities (Low) – During the forecast period, the shift toward complex biologics and novel modalities will propel the growth of the pharma ADMET testing market. As pharmaceutical research increasingly embraces advanced biologic drugs, gene therapies, antibody–drug conjugates, and other novel modalities, there is rising demand for specialized ADMET and safety assessment workflows tailored to the unique pharmacokinetic and metabolic behaviors of these therapies. These complex biologics often require customized absorption, distribution, metabolism and excretion studies, as well as in-depth toxicity profiling, to ensure safe and effective clinical translation. As more drug developers focus on these next-generation therapeutic formats, the need for robust, modality-specific ADMET testing services will expand substantially, thereby driving growth in the pharma ADMET testing market. The shift toward complex biologics and novel modalities during the forecast period in 2025 is 0.5%. • Growth in Multi-Omics Integration (Low) – During the forecast period, the growth in multi-omics integration will emerge as a major factor driving the expansion of the market by 2030. as drug developers increasingly combine insights from genomics, proteomics, metabolomics and transcriptomics, there is a growing need for advanced admet testing frameworks capable of interpreting complex biological interactions. multi-omics integration supports deeper understanding of metabolic pathways, toxicity mechanisms and individual variability in drug response, enabling more accurate prediction of safety and efficacy profiles. as pharmaceutical companies adopt these multi-layered analytical approaches to enhance decision-making, reduce late-stage failures and strengthen precision-medicine initiatives, the demand for comprehensive, data-rich admet testing solutions will rise substantially, thereby driving the growth of the pharma admet testing market. as a result, the growth in multi-omics integration is anticipated to contributing to a 1.0% annual growth in the market • Rising Public Scrutiny of Drug Safety (Low) – During the forecast period, the rising public scrutiny of drug safety within digital manufacturing processes will serve as a key growth catalyst for the market by 2030. growing awareness among patients, regulators and advocacy groups about adverse drug reactions and long-term safety has increased pressure on pharmaceutical companies to ensure rigorous safety evaluation before drug approval and market release. this heightened scrutiny drives demand for comprehensive adme, toxicology and pharmacokinetic testing to detect potential adverse effects early and to ensure regulatory compliance. as transparent reporting systems and real-world safety monitoring become more widespread, the requirement for robust preclinical and translational admet testing will grow, thereby fueling expansion in the pharma admet testing market. therefore, this rising public scrutiny of drug safety across digital manufacturing operations is projected to supporting to a 0.8% annual growth in the market.

How Will The Restraints Impact Growth In The Global Pharma ADMET Testing Market?

• High Cost of Preclinical Testing and Toxicology Requirements (Medium) – During the forecast period, high cost of preclinical testing and toxicology requirements is restricting the growth of the pharma admet testing market during the forecast period. conducting comprehensive adme, safety, and toxicity studies demands substantial financial investments in specialized facilities, regulatory compliance, and rigorous laboratory operations, which can deter smaller biotech firms and emerging drug developers. the burden of these costs can lead to postponements or reductions in the number of drug candidates entering full preclinical evaluation, shrinking the volume of testing demand. as a result, many companies may opt for minimal or truncated preclinical assessment, or delay development altogether, which suppresses growth in the admet testing services market. growth affected by high cost of preclinical testing and toxicology requirements during the forecast period in 2025 is -2.0%. • Long Duration of ADMET Studies Delays Development Timelines (Low) – During the forecast period, long duration of admet studies delays development timelines is restricting the growth of the pharma admet testing market during the forecast period. extensive adme, safety and toxicity testing procedures often require prolonged in-vitro and in-vivo evaluation, detailed data collection, and multiple rounds of analysis before regulatory submission. these time-consuming processes increase overall drug development lead times, potentially discouraging sponsors from pursuing full admet assessment, especially when rapid development or competitive speed to market is a priority. as a result, demand for comprehensive admet testing may decline in favor of faster, but potentially less thorough, development paths, thereby limiting growth of the pharma admet testing market. growth affected by long duration of admet studies delays development timelines during the forecast period in 2025 is -1.0%. • Impact of Trade War and Tariff (Low) – During the forecast period, impact of trade war and tariffs is restricting the growth of the pharma admet testing market during the forecast period. escalating tariffs and trade tensions, especially between major chemical and pharmaceutical supply hubs, are raising the cost of raw materials, apis, reagents and lab supplies needed for preclinical admet testing, thereby increasing operational costs for testing providers. this cost inflation, along with supply-chain disruptions and import delays, undermines the accessibility and reliability of essential inputs for adme, toxicity and dmpk studies. as companies face uncertainty and higher overheads, some may reduce the number of compounds submitted for full admet profiling or delay testing altogether, weakening demand for testing services. growth affected by impact of trade war and tariffs during the forecast period in 2025 is -0.3%.

Key Players In The Global Pharma ADMET Testing Market

Major companies operating in the pharma admet testing market are Thermo Fisher Scientific Inc., The Merck Group, Laboratory Corporation of America Holdings, IQVIA Inc., PPD ICON plc, Agilent Technologies Inc., Wuxi AppTec Co. Ltd., Catalent Inc., Covance Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, Beckman Coulter Inc., Perkinelmer Inc., Albany Molecular Research Inc., Evotec A.G., CMIC Holdings Co. Ltd., Promega Corporation, Aptuit LLC, Symeres B.V., Biovia Corp., BioIVT LLC, Cyprotex Limited, InSphero AG, Admescope Ltd., Accelrys Inc.

Global Pharma ADMET Testing Market Trends and Insights

Major companies in the pharma ADMET testing market are introducing innovative products such as artificial intelligence-driven drug design, which allows for automated de novo generation of novel small molecule structures. Artificial intelligence-driven drug design refers to the use of artificial intelligence (AI) to design and optimize drug molecules without relying solely on traditional lab-based screening or manual medicinal chemistry. For instance, in June 2025, Simulations Plus Inc., a US-based company specializing in cheminformatics software for the pharmaceutical sector, launched ADMET Predictor 13, an advanced artificial intelligence-driven drug-design and ADMET-prediction platform integrating enhanced high-throughput PBPK simulations and a generative AI-enabled drug-design engine (AIDD). Additionally, it offers streamlined workflows enabling faster and more informed decision-making in drug development.

What Are Latest Mergers And Acquisitions In The Pharma ADMET Testing Market?

In November 2024, Concept Life Sciences Limited, a UK-based integrated drug discovery and development company specializing in medicinal chemistry, acquired Charnwood Discovery Ltd for an undisclosed amount. Through this acquisition, Concept Life Sciences aims to enhance its drug discovery and development capabilities by integrating Charnwood’s expertise in medicinal chemistry and ADME/ADMET testing services, thereby streamlining early-stage drug development and offering end-to-end solutions to a broader pharmaceutical and biotech customer base. Charnwood Discovery is a UK-based contract research organization specializing in medicinal ADMET testing services.

What Defines the Pharma ADMET Testing Market?

The pharma ADMET testing market consists of revenues earned by entities by providing services such as in vitro screening, in vitro metabolism, and metabolite testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharma ADMET testing market also includes the sales of membranes, buffer systems, and analytes that are used in the assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pharma ADMET Testing Market Report 2026?

The pharma admet testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pharma admet testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.